Belite Bio (BLTE) Net Cash Flow (2024 - 2025)
Belite Bio (BLTE) posted quarterly Net Cash Flow of $196.0 million for Q4 2025, up 2039.73% year-over-year from $9.2 million in Q4 2024, and up 2039.73% quarter-over-quarter from $9.2 million in Q4 2024.
Belite Bio (BLTE) Net Cash Flow (2024 - 2025) Analysis & Trends
Belite Bio's Net Cash Flow history runs 2 years deep, the most recent figure standing at $196.0 million for Q4 2025.
- In Q4 2025, Net Cash Flow rose 2039.73% year-over-year to $196.0 million; the TTM figure through Mar 2026 stood at $196.0 million (up 2039.73% YoY), while the FY2025 annual figure was $321.1 million, up 671.31% from the prior year.
- Net Cash Flow for Q4 2025 stood at $196.0 million, up from $9.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $196.0 million in Q4 2025, with the low at $9.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 196.00 Mn |
| Dec 31, 2025 | 196.00 Mn |
| Dec 31, 2024 | 9.16 Mn |
| Dec 31, 2024 | 9.16 Mn |